Needs/Wishes for Innovation
Businesses looking for similar products or services There are currently no matches found. Please check back at a later time. |
BAKBlock Cancer Therapeutic (05037) - Veterinary Apoptosis inducing cancer therapeutic for treating cancer in animals There are currently no reviews for this Innovation.
| BAKBlock Cancer Therapeutic (05037) - Veterinary
Apoptosis inducing cancer therapeutic for treating cancer in animals |
|
BAKBlock prevents out of control cancer cell growth, prevents cancer from spreading, & can restore the effectiveness of other cancer drugs- cells die when they are told to. |
 Annual Sales Forecast for USA * | Innovation Status |
Idea |
Sales & Marketing
Support Level |
Conservative
80% odds
of selling |
Most Likely
50% odds
of selling |
Aggressive
20% odds
of selling |
Development
Status |
Proprietary
Protection Status |
Concept
Score |
| Ultra Low |
$2,900 |
$424.3 M |
$1.9 B |
2 of 5
Successful Prototypes
|
2 of 5
Patent Pending
|
63 29 is
Average
|
| Low Support |
$4.8 B |
$10.0 B |
$19.5 B |
| Medium Support |
$36.5 B |
$65.4 B |
$112.3 B |
| High Support |
$94.2 B |
$167.9 B |
$289.7 B |
Remaining Time & Cost to First Sale |
| Ultra High |
$168.7 B |
$299.9 B |
$510.9 B |
Unknown
|
Unknown
|
BAKBlock Cancer Therapeutic (05037) - Veterinary
- Apoptosis inducing cancer therapeutic for treating cancer in animals
Final Decision Maker: Owners of pets with cancer
BAKBlock prevents out of control cancer cell growth, prevents cancer from spreading to new sites, and can restore the effectiveness of other cancer drugs. In the presence of BAKBlock, the cells die when they are told to. Cancer cells grow faster and live longer than normal cells, sometimes because they resist (or don't "hear") normal signals to die. Apoptosis (programmed cell death) is a normal part of the regulatory control of all cells, but it does not function properly in cancer cells so they don't die when they should. BAKBlock restores the proper response in the cancer cells. How? BAKBlock works by binding to a protein in the cell that prevents programmed cell death. When BAKBlock is added, the inhibitor is stopped, and the tumor cells commit suicide. Cancer in animals is currently treated with chemotherapy, radiation therapy, surgery, and targeted therapy directed specifically toward the tumor cells. BAKBlock is a new kind of targeted therapy. The patent application described that BAKBlock was tested on nude mice with PC3 prostate cancers. The mice were given the BAKBlock orally for 63 days (dosage according to body weight). Results showed that tumor growth was reduced by up to 61%, with no toxicity. BAKBlock is a small molecule that can be made by synthetic chemistry. Thus it will be cheaper than larger more complex drugs like monoclonal antibodies. The lead inventor is a professor of Medicinal Chemistry in the College of Pharmacy at The Ohio State University. He has published over 160 scientific papers in peer reviewed journals. He has a successful history of developing small molecules, some which have been licensed to drug development companies for cancer treatment. The National Institute of Health has funded his work.
| $50,000 for 60 days of oral treatment | Seeking: Purchase |
|
* Consumption sales forecast. Does not include "Random" events or "Inventory Fill". Forecast is for Year 1 for Large or Year 2 for Small Companies.
Forecast should be read as ..."With Low marketing support there is an 80% odds of achieving sales of at least... |
| Listing #: USA.76.020210.002 |
Page 1 of 5 |
Date Posted: 2010-02-09 |
|
| ©2008. Eureka! Institute. All Rights Reserved. Patents Granted or Pending Eureka! Ranch International www.EurekaRanch.com (513) 271-9911 |
|
Report Assumptions and Inventor(s) Commentary
|
|
| Inventor(s) Assumptions |
"Most Likely"
Estimate |
Confidence |
Inventor(s) Commentary
Data Source or Basis for Assumptions |
| # of Possible Final Decision Makers |
17,600,000 |
10% |
American Vet. Med. Assoc. website- # of dogs & cats in US is 75M & 81M respectively & estimation studies have shown 33% of dogs & 13% of cats get cancer-assume 2 animals per owner
|
| Revenue per First Purchase |
$50,000.00 |
10% |
Based on cost of structurally related molecule which sells for $50 per bottle of 28 tablets at 15mg each; and on dosage used in patent to treat mice of 100mg/kg/day |
| % that will Repeat |
45% |
10% |
Repeat rate dependent on animals tolerance of the therapy, death rate and prevalence of disease, as well as owners ability to treat their pet. |
| Number of Annual Repeats |
5 |
10% |
Based on a 60 day supply with pet owner repurchasing every 2 months. |
| Revenue per Repeat Purchase |
$50,000.00 |
10% |
Same as first purchase. This supply is for a 60 day period so patient would repurchase an equivalent amount every 2 months. |
| Reseller (Trade) Margin |
50% |
10% |
Based on industry standard. |
| Producer Profit (EBITD) |
15% |
10% |
Based on reference data provided for pharmaceutical and medicine manufacturing. |
| |
| Innovation Status |
|
Development
Status |
2 of 5
Successful Prototypes
|
Initial tested has revealed successful prototypes but further prototyping development and testing (animal trials) is required |
| Cost to First Sale (remaining) |
Unknown |
10% |
unknown |
| Time to First Sale (remaining) |
Unknown |
10% |
unknown |
| Confidence in Concept Claims made in description |
40% |
Concept based on information provided by technology licensing associate and testing for initial claims performed by inventor of technology |
Proprietary
Protection Status |
2 of 5
Patent Pending
|
International patent application filed |
| Concept Score & Diagnostics |
|
|
| Concept Diagnostics |
Red |
Yellow |
Green |
| Percentile Group |
Bottom 40% |
Middle 40% |
Top 20% |
| Overt Benefit |
 |
|
|
| Reason to Believe |
|
 |
|
| Dramatic Difference |
|
|
 |
|
| Listing #: USA.76.020210.002 |
Page 2 of 5 |
Date Posted: 2010-02-09 |
| ©2008. Eureka! Institute. All Rights Reserved. Patents Granted or Pending Eureka! Ranch International www.EurekaRanch.com (513) 271-9911 |
|
Inventor Commentary & Alternative Development Scenarios
|
|
| Inventor(s) Sales Goals |
| Minimum Goal |
$- |
Current GOAL |
$- |
Tumor formation through loss of normal growth control
Source: (http://www.cancer.gov/cancertopics/understandingcancer/cancer/) |
Inventor(s) Commentary:
NOTE: This innovation is represented by The Ohio State University and was input by the Planet Eureka! Team who is solely responsible for its content. All cost and pricing information was estimated by the Planet Eureka! Team. To access more complete information simply click on “Link to Website With More Complete Info” or on “Email Inventor(s)” on the bottom of page 1 of this report. |
|
CURRENT SALES FORECAST |
Sales & Marketing
Support Level |
Conservative
80% odds
of selling |
Most Likely
50% odds
of selling |
Aggressive
20% odds
of selling |
| Ultra Low |
$2,900 |
$424.3 M |
$1.9 B |
| Low Support |
$4.8 B |
$10.0 B |
$19.5 B |
| Medium Support |
$36.5 B |
$65.4 B |
$112.3 B |
| High Support |
$94.2 B |
$167.9 B |
$289.7 B |
| Ultra High |
$168.7 B |
$299.9 B |
$510.9 B |
If MARKETING CONCEPT Improved (Increase Concept Score by +20 Points) |
Sales & Marketing
Support Level |
Conservative
80% odds
of selling |
Most Likely
50% odds
of selling |
Aggressive
20% odds
of selling |
| Ultra Low |
$3,800 |
$570.7 M |
$2.4 B |
| Low Support |
$6.4 B |
$13.3 B |
$25.6 B |
| Medium Support |
$48.9 B |
$86.2 B |
$147.8 B |
| High Support |
$126.5 B |
$221.3 B |
$383.0 B |
| Ultra High |
$225.0 B |
$395.1 B |
$676.8 B |
If PRODUCT/SERVICE Improved (Increase Repeat Rate & Number of Repeats by 30% and Revenue Per Purchase 20%) |
Sales & Marketing
Support Level |
Conservative
80% odds
of selling |
Most Likely
50% odds
of selling |
Aggressive
20% odds
of selling |
| Ultra Low |
$4,900 |
$664.8 M |
$3.1 B |
| Low Support |
$7.4 B |
$16.7 B |
$34.3 B |
| Medium Support |
$55.4 B |
$109.9 B |
$206.8 B |
| High Support |
$141.6 B |
$283.2 B |
$520.3 B |
| Ultra High |
$252.1 B |
$505.7 B |
$931.8 B |
If MARKETING CONCEPT and PRODUCT/SERVICE Improved (Increase Concept +20 Points, Repeat Rate & Number of repeats by 30% and Revenue per purchase 20%) |
Sales & Marketing
Support Level |
Conservative
80% odds
of selling |
Most Likely
50% odds
of selling |
Aggressive
20% odds
of selling |
| Ultra Low |
$6,300 |
$884.6 M |
$4.2 B |
| Low Support |
$9.9 B |
$22.1 B |
$45.1 B |
| Medium Support |
$74.0 B |
$143.6 B |
$269.4 B |
| High Support |
$191.2 B |
$376.0 B |
$684.2 B |
| Ultra High |
$341.1 B |
$663.6 B |
$1,218.6 B |
|
| Listing #: USA.76.020210.002 |
Page 3 of 5 |
Date Posted: 2010-02-09 |
| ©2008. Eureka! Institute. All Rights Reserved. Patents Granted or Pending Eureka! Ranch International www.EurekaRanch.com (513) 271-9911 |
|
Additional Details
|
|
| Fair Market Royalty (%) |
| |
Conservative - 80% Odds
Royalty Percentage |
Most Likely - 50% Odds
Royalty Percentage |
Aggressive - 20% Odds
Royalty Percentage |
| At CURRENT State & Status |
1.8% |
2.4% |
3% |
Sales & Marketing
Support Level |
Annual Inventor Royalty Revenue |
3 Year Value
to Inventor
If 50% Odds |
| 80% Odds |
50% Odds |
20% Odds |
| Ultra Low Support |
$3.4 M |
$8.5 M |
$16.3 M |
$25.5 M |
| Low Support |
$55.0 M |
$113.9 M |
$194.7 M |
$341.6 M |
| Medium Support |
$379.1 M |
$717.4 M |
$1.1 B |
$2.2 B |
| High Support |
$959.3 M |
$1.9 B |
$3.0 B |
$5.6 B |
| Ultra High Support |
$1.7 B |
$3.3 B |
$5.3 B |
$10.0 B |
| Sales & Marketing Support Level Assumptions |
| Sales & Marketing Support Level Assumptions |
Sample Numbers |
% Aware x
% Distribution
(Aware & Able) |
Inventor
Confidence |
| % Distribution |
% Awareness |
| Ultra Low Support (Word of Mouth) |
5% |
3% |
0.2% |
N/A |
| Low Support (Small Company) |
20% |
10% |
2% |
% |
| Medium Support (Medium Sized Company) |
50% |
25% |
13% |
N/A |
| High Support (Large Company) |
75% |
45% |
34% |
N/A |
| Ultra High Support (Mega or Niche) |
90% |
70% |
63% |
N/A |
|
Graph of EQUIVALENT (Awareness x Distribution) Combinations
 |
NAICS Industry Codes
For This Invention |
| 54171 - Research and Development in the Physical, Enginee... |
| 32541 - Pharmaceutical and Medicine Manufacturing |
| |
| |
| |
|
| Patent Numbers that apply to this Product/Service |
| PCTUS2005/056454 |
| |
| |
| |
| |
|
| Inventor(s) PEDIGREE |
| Years EXPERIENCE in related industry |
25 |
| GRANTED Patents |
- |
| Licensing Deals SIGNED |
- |
| Innovations that have SHIPPED |
- |
|
For USA Patents: Utility Patent = 7 digit number, Design Patent starts with D, Planet Patent starts with PP. Provisional Application "61/xxx,xxx", Non provisional application "12/xxx,xxx", Design patent application "29/xxx,xxx"
|
|
CAUTION: This Merwyn Business Simulation Research Report includes no warranty or guarantee. Results and opinions should be considered rough and directional in nature. This is because the report is based upon inventor-supplied data and simplified modeling methods. If you are looking to invest, distribute, purchase or become involved with this innovation, in any way, we strongly urge you to validate the inventor data and sales forecasts BEFORE committing yourself or your resources. Merwyn Research, Inc. shall not be responsible for any liability or damages arising out of the failure to perform such investigation and validation. Changes in the concept description, product, pricing, or input assumptions will almost certainly change results.
|
| Listing #: USA.76.020210.002 |
Page 4 of 5 |
Date Posted: 2010-02-09 |
| ©2008. Eureka! Institute. All Rights Reserved. Patents Granted or Pending Eureka! Ranch International www.EurekaRanch.com (513) 271-9911 |
|
Additional Forecasts for Other Countries
|
|
 Annual Sales - Probability Forecast - Canada |
Sales & Marketing
Support Level |
Conservative
80% odds
of selling |
Most Likely
50% odds
of selling |
Aggressive
20% odds
of selling |
| Ultra Low |
$460 |
$67.2 M |
$295.6 M |
| Low Support |
$760.1 M |
$1.6 B |
$3.1 B |
| Medium Support |
$5.8 B |
$10.4 B |
$17.8 B |
| High Support |
$14.9 B |
$26.6 B |
$45.9 B |
| Ultra High |
$26.7 B |
$47.5 B |
$81.0 B |
 Annual Sales - Probability Forecast - United Kingdom |
Sales & Marketing
Support Level |
Conservative
80% odds
of selling |
Most Likely
50% odds
of selling |
Aggressive
20% odds
of selling |
| Ultra Low |
$820 |
$119.3 M |
$524.5 M |
| Low Support |
$1.3 B |
$2.8 B |
$5.5 B |
| Medium Support |
$10.3 B |
$18.4 B |
$31.6 B |
| High Support |
$26.5 B |
$47.2 B |
$81.5 B |
| Ultra High |
$47.4 B |
$84.3 B |
$143.7 B |
Forecast are calculated based on population, (PPP) purchasing power parity, International Trade, Urbanization and the Human Growth Index.
Forecast can be skewed for some industries, so for best results, adjusting the number of final decision makers for every country is recommended.
| Listing #: USA.76.020210.002 |
Page 5 of 5 |
Date Posted: 2010-02-09 |
| ©2008. Eureka! Institute. All Rights Reserved. Patents Granted or Pending Eureka! Ranch International www.EurekaRanch.com (513) 271-9911 |
|
